Clinical trials: Intestines
Crohn's Disease
Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to severe Crohn's Disease (CD).
- Trial name
- NCT05057273
- Testing
- BT-11, Active comparator
- Sponsor
- NImmune Biopharma
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Diarrhea
Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.
This study aims to assess elemental impurities level after dministration of dioctahedral smectite in subjects with functional diarrhea or irritable bowel syndrome with predominant diarrhea.
- Trial name
- NCT05816681
- Testing
- DWJ1230, DWB2001
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to…
- Trial name
- GARDENIA (NCT02136069)
- Testing
- Etrolizumab, Infliximab
- Where
- 119 sites in Austria, Belgium and 18 more
- Volunteers
- 397 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Healthy Adult Participants, Gut Microbiomes
DORA - A Study Using Digital Health Tools/Platform to Explore the Impact of the Consumption of Senior Milk Powder Containing Synbiotics on the Gut micRobiome in Healthy Aging Individuals
The DORA study is a single-arm, open-label, interventional exploratory study designed to evaluate the impact of a synbiotic-containing senior milk powder on the gut microbiome and selected biological, physiological, and digital…
- Conditions
- Healthy Adult Participants, Gut Microbiomes, AI
- Trial name
- DORA (NCT07575529)
- Testing
- Synbiotic Nutritional Product
- Where
- Singapore
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Danone Asia Pacific Holdings Pte, Ltd.
Barrett Esophagus
HALO Patient Registry: Ablation of Barrett's Esophagus
The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD).
- Trial name
- NCT00848237
- Testing
- Radiofrequency Ablation (HALO Ablation Systems)
- Where
- United States
- Volunteers
- 5,521 people
- Sponsor
- Medtronic - MITG
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Colorectal Cancer, Gastric Cancer
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer.
- Conditions
- Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
- Trial name
- NCT02191761
- Testing
- SM04755
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biosplice Therapeutics, Inc.
Ulcerative Colitis
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.
- Trial name
- NCT07265570
- Testing
- ISM5411 tablets
- Where
- 28 sites in China
- Volunteers
- 80 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Crohn Disease
A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
Crohn's Disease (CD) is a chronic pathology characterized by exacerbations and remissions. Recurrent inflammation can cause bowel strictures, fistulae (often perianal) or abscesses. CD often requires intestinal resection.
- Trial name
- STOP-PER (NCT03537157)
- Testing
- Rifaximin delayed release tablets
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Alfasigma S.p.A.
Ulcerative Colitis
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
- Trial name
- NCT00355901
- Testing
- Visilizumab (Nuvion®; HuM291)
- Where
- 40 sites in United States, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- PDL BioPharma, Inc.
Inflammatory Bowel Diseases
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
A First-Time-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers
- Trial name
- NCT00721812
- Testing
- GSK1399686
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colitis, Ulcerative
Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
The purpose of this study is to allow subjects completing study LYC-30937-2001 the opportunity to receive LYC-30937-EC 25 mg.
- Trial name
- NCT02764229
- Testing
- LYC-30937-EC
- Where
- 40 sites in United States, Czechia and 4 more
- Volunteers
- 112 people
- Sponsor
- Lycera Corp.
Helicobacter Pylori Infection, Gastrointestinal Dysbiosis
Bacillus Probiotics With Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is a very common gastrointestinal disease that colonises the human gastric mucosa and is a primary risk factor for chronic gastritis, peptic ulcer disease, and gastric cancer.
- Conditions
- Helicobacter Pylori Infection, Gastrointestinal Dysbiosis, Antibiotic-associated Adverse Events
- Trial name
- NCT07827170
- Testing
- RO water, LiveSpo CLAUSY, LiveSpo DIA30
- Where
- Vietnam
- Volunteers
- 336 people
- Sponsor
- Anabio R&D
Irritable Bowel Syndrome
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome
The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).
- Trial name
- ALFA (NCT01243853)
- Testing
- Alpha-galactosidase
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Verman Oy Ab
Metastatic Colorectal Cancer
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX.
- Trial name
- NCT03035253
- Testing
- OMP-305B83, FOLFIRI, FOLFOX
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Perianal Fistula, Crohn's Disease
Study of ExoFlo for the Treatment of Perianal Fistulas
To evaluate the safety and feasibility of ExoFlo as a treatment for Perianal Fistulizing Crohn's Disease.
- Trial name
- NCT05836883
- Testing
- ExoFlo, Local injection of normal saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Direct Biologics, LLC
Exocrine Pancreatic Insufficiency, Pancreatitis, Chronic
A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)
The purpose of the study is to evaluate the enzyme activity and safety of pancrelipase in patients with severe Exocrine Pancreatic Insufficiency (EPI)
- Conditions
- Exocrine Pancreatic Insufficiency, Pancreatitis, Chronic, Steatorrhea, Pancreatitis
- Trial name
- NCT00676702
- Testing
- Ensure Plus, Pancrelipase in combination with Ensure Plus
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.